Comparative Pharmacology
Head-to-head clinical analysis: LOXITANE IM versus TREMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOXITANE IM versus TREMIN.
LOXITANE IM vs TREMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LOXITANE IM (loxapine) is a dibenzoxazepine antipsychotic. Its mechanism of action is not fully established but is thought to be mediated via antagonism of central dopamine D2 and serotonin 5-HT2A receptors. It has high affinity for D2, D3, D4, and 5-HT2A receptors and low affinity for D1 receptors. It also has moderate affinity for histamine H1 and alpha1-adrenergic receptors.
Trihexyphenidyl is a centrally acting anticholinergic agent that blocks muscarinic acetylcholine receptors in the basal ganglia, restoring the balance between dopaminergic and cholinergic activity, thereby reducing extrapyramidal symptoms.
Adults: 12.5-50 mg IM every 4-6 hours as needed, not to exceed 150 mg/day.
1 mg orally 1-2 times daily, gradually increasing by 1 mg every 5-7 days up to 12 mg/day in divided doses. Maximum dose 12 mg/day.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours. Clinically, steady-state reached in 2-3 days; dosing interval based on q6-12h.
Terminal elimination half-life: 16 hours (range 12–20 hours) in adults, supporting twice-daily dosing; 35 hours in elderly patients
Primarily renal: 70% as metabolites; biliary/fecal: 30% as metabolites and unchanged drug.
Renal: 40% unchanged; fecal: 60% as metabolites
Category C
Category C
Antipsychotic
Antipsychotic